MEP22608A - Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors - Google Patents

Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors

Info

Publication number
MEP22608A
MEP22608A MEP-226/08A MEP22608A MEP22608A ME P22608 A MEP22608 A ME P22608A ME P22608 A MEP22608 A ME P22608A ME P22608 A MEP22608 A ME P22608A
Authority
ME
Montenegro
Prior art keywords
nr5r6
cycloalkyl
alkyl
optionally substituted
alkenyl
Prior art date
Application number
MEP-226/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Marcel Patek
Anil Nair
Augustin Hittinger
Conception Nemecek
Daniel Bond
Greg Harlow
Herve Bouchard
Jacques Mauger
Jean-Luc Malleron
Mark Palermo
Fahad Al-Obeidi
Thomas Faitg
Hartmut Strobel
Sven Ruf
Kurt Ritter
Youssef El-Ahmad
Dominique Lesuisse
Didier Benard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MEP22608A publication Critical patent/MEP22608A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MEP-226/08A 2003-01-31 2004-01-28 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors MEP22608A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301098A FR2850652B1 (fr) 2003-01-31 2003-01-31 Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
PCT/FR2004/000188 WO2004070050A2 (fr) 2003-01-31 2004-01-28 Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
MEP22608A true MEP22608A (en) 2010-06-10

Family

ID=32696243

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-226/08A MEP22608A (en) 2003-01-31 2004-01-28 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors

Country Status (24)

Country Link
EP (1) EP1599464B1 (de)
JP (1) JP4604020B2 (de)
KR (1) KR20050098286A (de)
CN (1) CN1768054A (de)
AR (1) AR042936A1 (de)
AT (1) ATE482207T1 (de)
AU (1) AU2004209319A1 (de)
BR (1) BRPI0407091A (de)
CA (1) CA2513631A1 (de)
DE (1) DE602004029236D1 (de)
FR (1) FR2850652B1 (de)
HR (1) HRP20050679A2 (de)
MA (1) MA27651A1 (de)
ME (1) MEP22608A (de)
MX (1) MXPA05007407A (de)
NO (1) NO20054006L (de)
NZ (1) NZ541270A (de)
PE (1) PE20040808A1 (de)
PL (1) PL377811A1 (de)
RS (1) RS20050657A (de)
RU (1) RU2341523C2 (de)
TW (1) TW200505898A (de)
WO (1) WO2004070050A2 (de)
ZA (1) ZA200505934B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027546T2 (en) 2003-08-29 2016-10-28 Brigham & Womens Hospital Inc Hydantoin derivatives as cell necrosis inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP2299266A1 (de) 2003-12-19 2011-03-23 The Regents of the University of California Verfahren und Materialien zur Beurteilung von Prostatakrebstherapien
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP1621535A1 (de) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Cyclische Substituirte Harnstoffderivate, Verfahren zu ihrer Herstellung, und ihre pharmazeutische Verwendung als Kinase Inhibitoren
EP1621536A1 (de) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino zyklische Urea-Derivaten, ihre Herstellung und deren pharmazeutische Verwendungen als Kinase Inhibitoren
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
DK2444085T3 (en) 2005-05-13 2015-04-27 Univ California Diarylhydantoinforbindelser as androgenreceptorantagonister for treating cancer
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
FR2896504B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
DK2656841T3 (en) 2006-03-27 2016-12-05 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
RU2449993C2 (ru) 2006-03-29 2012-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Диарилтиогидантоиновые соединения
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
CA2772760A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
WO2011103202A2 (en) 2010-02-16 2011-08-25 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
AU2011349525B2 (en) * 2010-12-21 2015-05-21 Cytec Technology Corp. Microdispersions of hydroxamated polymers and methods of making and using them
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
KR20220025231A (ko) 2012-09-26 2022-03-03 아라곤 파마슈티컬스, 인코포레이티드 비전이성 거세 저항성 전립선암 치료용 항안드로겐
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
GB201312492D0 (en) * 2013-07-12 2013-08-28 Syngenta Ltd Herbicidal compounds
EP3094326A4 (de) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryle und verwendungen davon
GEP20196983B (en) 2014-01-14 2019-06-25 Millennium Pharm Inc Heteroaryls and uses thereof
AU2015360291A1 (en) 2014-12-11 2017-07-13 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
TWI806385B (zh) * 2016-07-20 2023-06-21 瑞士商諾華公司 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
KR102247795B1 (ko) * 2017-10-31 2021-05-04 주식회사 펠레메드 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
PL336580A1 (en) * 1997-03-03 2000-07-03 Boehringer Ingelheim Pharma Fine-molecular compounds useful in treating inflammatory diseases
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
IL152961A0 (en) * 2000-05-31 2003-06-24 Tanabe Seiyaku Co Inhibitors of alpha beta 2 mediated cell adhesion
KR101019778B1 (ko) * 2002-05-16 2011-03-04 바이엘 크롭사이언스 게엠베하 피리딘 카복사마이드 유도체 및 이것의 살충제로서의 용도

Also Published As

Publication number Publication date
PL377811A1 (pl) 2006-02-20
NO20054006L (no) 2005-10-13
AR042936A1 (es) 2005-07-06
NZ541270A (en) 2008-11-28
WO2004070050A3 (fr) 2005-02-17
MA27651A1 (fr) 2005-12-01
TW200505898A (en) 2005-02-16
DE602004029236D1 (de) 2010-11-04
RS20050657A (en) 2007-06-04
AU2004209319A1 (en) 2004-08-19
FR2850652A1 (fr) 2004-08-06
MXPA05007407A (es) 2005-09-12
ATE482207T1 (de) 2010-10-15
CA2513631A1 (fr) 2004-08-19
KR20050098286A (ko) 2005-10-11
BRPI0407091A (pt) 2006-01-24
RU2005127335A (ru) 2006-09-10
HRP20050679A2 (en) 2006-12-31
ZA200505934B (en) 2007-06-27
EP1599464B1 (de) 2010-09-22
NO20054006D0 (no) 2005-08-29
FR2850652B1 (fr) 2008-05-30
CN1768054A (zh) 2006-05-03
JP4604020B2 (ja) 2010-12-22
JP2006517569A (ja) 2006-07-27
RU2341523C2 (ru) 2008-12-20
WO2004070050A2 (fr) 2004-08-19
EP1599464A2 (de) 2005-11-30
PE20040808A1 (es) 2004-12-31

Similar Documents

Publication Publication Date Title
MEP22608A (en) Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors
TW200617004A (en) Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20052993L (no) 4,5-diaryltiazolderivater som CB-1 ligander.
MXPA03010129A (es) N-aroilaminas-ciclicas.
NO20082976L (no) Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
NO20063780L (no) Fremgangsmate for fremstilling av 2-aminitiazol-5-aromatisk karboksamid som kinase inhibitorer.
HUP0500339A2 (hu) GSK3-mal kapcsolatos állapotok kezelésére használható aril-aminok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20080456L (no) Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer
NO20061406L (no) Organiske forbindelser
SE0104140D0 (sv) Novel Compounds
NO20065830L (no) Substituerte 2-kinolyloksazoler som er anvendbare som PDE4-inhibitorer.
ME00590A (en) N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof
WO2004069793A3 (en) Novel 2-substituted cyclic amines as calcium sensing receptor modulators
DE602005012811D1 (de) Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd
TWI256953B (en) Pyrimidine compounds
ATE507229T1 (de) Cucurbiturilderivate, die in wasser und organischen lösungsmitteln löslich sind, verfahren zu deren herstellung, verfahren zu deren trennung und deren anwendung
DE60142934D1 (de) Pharmazeutische dopamin-glykokonjugat-zusammensetzungen und verfahren zu deren herstellung
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
SE0303541D0 (sv) New compounds
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20061045L (no) Imidazolderivater
MXPA05007848A (es) Derivados de arilalquilcarbamatos, su preparacion y su aplicacion en terapeutica.
NO20062202L (no) Amidometylsubstituerte 2-(4-sulfonylamino)-3-hydroksy-3,4-dihydro-2H-kromen-6-yl-derivater, fremgangsmate og mellomprodukter for deres fremstilling, og legemidler som inneholder disse forbindelsene
SE0303090D0 (sv) Novel compounds